Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive CholangiocarcinomaLipika Goyal, Andrew X. Zhu|Cancer Discovery|2016Cited by 539
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Funda Meric‐Bernstam et al.|New England Journal of Medicine|2023Cited by 530
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R. Parikh, Ryan B. Corcoran, Filippo Utro et al.|Nature Medicine|2019Cited by 521
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal CancerAparna R. Parikh, Ryan B. Corcoran, Emily E. Van Seventer et al.|Clinical Cancer Research|2021Cited by 358